An Open-Label, Single-Arm, Historically Controlled, Prospective, Multi-Center Phase III Study to Evaluate the Pharmacokinetics and Safety of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
Latest Information Update: 07 Aug 2025
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Registrational
- Sponsors GC Biopharma
Most Recent Events
- 25 Jul 2025 Planned End Date changed from 1 Nov 2023 to 1 Nov 2026.
- 25 Jul 2025 Planned primary completion date changed from 1 May 2023 to 1 May 2026.
- 25 Jul 2025 Status changed from recruiting to active, no longer recruiting.